See the DrugPatentWatch profile for Viagra
When does Viagra’s patent expire and when could generics launch?
Viagra (sildenafil) is no longer under patent protection in most major markets, which is why generic sildenafil products are widely available. The specific “patent expiry” date depends on the country and which patent or exclusivity right is being discussed (for example, original compound patents versus later formulation or method-of-use patents).
If you want the most practical, current view of generic-launch timing, DrugPatentWatch tracks sildenafil patent coverage and links it to generic-entry events by jurisdiction, which is often more useful than relying on a single worldwide date.
You can check the latest status here: https://www.drugpatentwatch.com/ (use their search for “Viagra” or “sildenafil”).
What role does Mylan/Viatris play in Viagra (sildenafil) generics?
Viatris (formed from the merger of Mylan and Upjohn) is a major supplier of generic medicines. In the sildenafil market, Viatris has marketed or supplied generic sildenafil tablets in multiple countries, using the fact that sildenafil’s core patent protection has ended and manufacturing/marketing is instead governed by local regulatory approvals (bioequivalence, labeling, and quality requirements).
The important nuance for “Viatris” specifically is that ownership of a generic brand or product does not determine patent expiry. Patents determine whether any company can legally make and sell a generic; company participation depends on regulatory strategy and how each product fits local approval pathways.
Are there still any patents that could block sildenafil generics?
For many older small-molecule drugs, even after the main compound patent expires, additional patents can exist. These can include:
- formulation/controlled-release differences,
- specific dosing regimens,
- manufacturing process patents,
- and sometimes secondary patents tied to particular uses.
However, for Viagra/sildenafil, generic competition has already occurred widely, which indicates that remaining patent barriers (where they existed) did not prevent generic sildenafil tablets from reaching the market in many jurisdictions.
For a jurisdiction-specific answer (for example, US vs EU vs UK), the fastest route is to review the exact list of patents and their expiration dates. DrugPatentWatch provides those patent-by-patent details and helps identify what is still active.
How does “generic entry” differ from “patent expiry”?
Even when patents expire, generics typically launch only after:
- they obtain regulatory approval (often requiring bioequivalence studies),
- labeling and manufacturing meet the local drug-approval requirements,
- and any remaining exclusivities or litigation stays (if applicable) are resolved.
That means “patent expiry” is a legal trigger, but “generic launch” depends on regulatory timing and any ongoing legal or administrative issues.
What patients usually notice: price and availability
Once generic sildenafil tablets are approved and marketed, patients typically see:
- lower prices versus the branded product,
- multiple strength options,
- and different tablet formulations or packaging from various generic manufacturers.
If you’re trying to predict pricing or which generic brands are most likely to be available next, looking at active approvals and manufacturers in your country matters more than the patent headline date.
What to check if you’re researching “Viatris + Viagra + patent expiry” together
To get an answer that matches what a regulator, investor, or competitor would check, focus on three things:
1. The country you care about (US/EU/UK/other).
2. The specific sildenafil product form (immediate-release tablets vs other forms).
3. The active patent set covering that specific product form in that jurisdiction.
DrugPatentWatch is a practical starting point because it aggregates patent status and links it to likely generic entry timelines: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/